FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention relates to novel compounds of the formula (I) or (II) taken among the mentioned below group showing activity with respect to calcium receptor, pharmaceutical composition and methods of treatment of diseases caused by anomalous and mineral homeostasis, hyperparathyroidism, hypercalcemia, malignant tumor, osteoporosis, hypertension and renal osteodystrophy. In compounds of the formula (I) or (II) Ar3, Ar4, Ar5, respectively, are taken among possibly substituted phenyl or naphthyl; Ar6 is taken among phenyl substituted with different substitutes under condition that at least one substitute means OCH2C(O)OC2H5. Values of other radicals are given in the invention claim. Also, invention relates to group of compounds taking among the following ones: 20Y (N-(2-chlorophenylpropyl)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethylamine); 21M ((R)-N-(3-(3-trifluoromethyl)propyl)-1-(3-methoxyphenyl)ethylamine); 21S ((R)-N-(3-(2-chlorophenyl)propyl)-1-(3-propoxyphenyl)ethyl-amine); 21T ((R)-N-(3-(2-chlorophenyl)propyl-1-(3-isopropoxyphenyl)-ethylamine; 21U ((R)-N-(3-(2-chlorophenyl)propyl)-1-(isobutoxy-phenyl)ethylamine; 21Y ((R, R)-N-(4-(3-trifluoromethyl)phenyl)-2- -butyl)-1-(3-methoxyphenyl)ethylamine; 22J ((R)-N-(3-(3-trifluoro-methyl)phenyl)propyl)-1-(1-naphthyl)ethylamine; 23A ((R)-N-(4-(3-trifluoromethoxy)phenyl)-2-butyl-1-(3-methoxyphenyl)ethylamine; 23E ((R)-N-((3-(trifluoromethoxy)phenyl)methyl)-1-(1-naphthyl)ethylamine; 23B (N-((3-methyl-4-methoxyphenyl)methyl)-1-(2-trifluoromethyl)-phenyl)ethylamine; 24J ((R)-N-(3-(3-trifluoromethoxy)phenyl)propyl)-1-(1-naphthyl)ethylamine; 24M ((R)-N-(3-(3,5-difluorophenyl)propyl)-1-(3-methoxyphenyl)ethylamine; 24V (N-((3-methyl-4-methoxy-phenyl)methyl)-1-(3-ethylacetoxy)phenyl)ethylamine; 24X ((R)-N-((3-bromo-4-methoxyphenyl)methyl)-1-(1-naphthyl)ethylamine; 24Y ((R)-N-((3-chloro-4-ethoxyphenyl)methyl)-1-(1-naphthyl)ethylamine; 25C ((S, R)-N-(4-(3-trifluoromethyl)phenyl)-2-butyl)-1-(1-naphthyl)- -ethylamine; 25D ((R,R)-N-(4-(3-trifluoromethyl)phenyl)-2-butyl-1-(1-naphthyl)ethylamine and 25E ((R)-N-(3-phenylprop-2-ene-1-yl)-1-(3-methoxyphenyl)ethylamine; or their pharmaceutically acceptable salt or complex. EFFECT: valuable medicinal properties of compounds, improved method of treatment. 32 cl, 3 tbl, 1 dwg, 163 fig, 18 ex
Title | Year | Author | Number |
---|---|---|---|
ARYLALKYLAMINES, COMPOSITIONS, METHODS OF TREATMENT AND DIAGNOSIS, METHOD OF IDENTIFICATION OF COMPOUND | 1992 |
|
RU2147574C1 |
PHARMACEUTICAL COMPOSITION SHOWING ACTIVITY WITH RESPECT TO CALCIUM RECEPTOR, METHOD OF PATIENT TREATMENT, METHOD OF ANALYSIS OF COMPOUND EXHIBITING EFFECT ON ACTIVITY OF INORGANIC ION RECEPTOR, RECEPTOR-ENCODING NUCLEIC ACID, CALCIUM RECEPTOR | 1993 |
|
RU2146132C1 |
COMPOUNDS BEING ACTIVE AT A NEW SITE UPON RECEPTOR-OPERATED CALCIUM CANALS APPLIED FOR TREATING NEUROLOGICAL DISORDERS | 1996 |
|
RU2246300C2 |
POLYPEPTIDE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS | 1993 |
|
RU2104286C1 |
COMPOUNDS ACTIVE IN NOVEL SITE ON RECEPTOR-REGULATING CALCIUM CHANNELS AND USED FOR TREATMENT OF NEUROLOGICAL DISTURBANCES AND DISEASES | 1994 |
|
RU2201224C2 |
POLYPEPTIDE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT (VARIANTS); METHOD TO SUPPRESS THE ACTION OF AMINO ACID NEUROMEDIATORS | 1993 |
|
RU2106358C1 |
POLYPEPTIDE DERIVATIVES, METHOD OF CALCIUM CHANNEL INHIBITION | 1993 |
|
RU2120945C1 |
PURINE L-NUCLEOSIDES, THEIR ANALOGUES AND USING | 1997 |
|
RU2183639C2 |
SMALL MOLECULE OF INHIBITORS OF ENZYMATIC ACTIVITY OF ROTAMASE | 1996 |
|
RU2186770C2 |
SMALL MOLECULES AS ROTAMASE ENZYME ACTIVITY INHIBITORS | 1996 |
|
RU2269514C9 |
Authors
Dates
2002-12-27—Published
1995-10-23—Filed